t细胞表面具有很多重要的分子，它们对于t细胞的活化、增殖和分化以及效应功能的发挥具有重要的作用。tigit是近年来新发现的一种具有免疫抑制功能的细胞表面蛋白，本文将就tigit蛋白的功能及药物开发现状进行回顾和…

TIGIT (/ ˈ t ɪ dʒ ɪ t / TIJ-it; [5] also called T cell immunoreceptor with Ig and ITIM domains) is an immune receptor present on some T cells and natural killer cells (NK). [6] It is also identified as WUCAM [7] and Vstm3. [8] TIGIT could bind to CD155 (PVR) on dendritic cells (DCs), macrophages, etc. with high affinity, and also to CD112 ...

TIGIT is an emerging immune checkpoint that inhibits immune cell responses at multiple steps of the cancer‐immunity cycle. TIGIT impairs T cell priming by dendritic cells, prevents tumour cell killing by Natural Killer cells and cytotoxic T cells, and enhances the immune suppressive activity of regulatory T cells.

T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to down-regulate T cel …

2023年7月26日 · This review mainly describes the immunosuppressive mechanism of TIGIT and its role in antitumor immunity of melanoma, so as to provide new ideas and schemes for the clinical treatment of melanoma...

tigit作为一种免疫抑制性受体，从发现至今才短短十几年，但已经作为免疫治疗的靶点进入临床试验。tigit是被寄予厚望的新的靶点，与pd-l1联合是未来有前途的抗癌治疗策略，两者可发挥协同抗肿瘤作用。

tigit的表达. tigit在淋巴细胞中表达，特别是在效应和调节性cd4+ t细胞，滤泡辅助cd4+ t细胞，效应cd8+ t细胞和自然杀伤（nk）细胞中高表达。 tigit的配体. cd155（也叫pvr 、necl5或tage4）是tigit的高亲和力配体。

2024年12月25日 · TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) is a Protein Coding gene. Diseases associated with TIGIT include Endocervical Carcinoma and Chromophobe Renal Cell Carcinoma. Among its related pathways are T cell modulation in pancreatic cancer and Interactions of natural killer cells in pancreatic cancer.

免疫治疗靶点后起之秀：tigit免疫检查点抑制剂已经成为癌症治疗的热门领域，其中以pd-1/pd-l1抑制剂为代表，已引起国内外药企的竞相布局。 但PD-1/PD-L1抑制剂在临床应用中仅有少数患者得到良好治疗，而且还出现耐…

其中一个靶标是具有免疫球蛋白 (ig) 和免疫受体酪氨酸抑制基序 (itim) 结构域的 t 细胞免疫受体 (tigit)。 什么是 tigit？ tigit 是在调节性 t 细胞、活化 cd8 + 和 cd4 + t 细胞以及自然杀伤 (nk) 细胞中表达的共抑制受体 1 。